Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Photos: Hundreds Gather at Bondi Beach After Deadly Attack- Vote In favor of Your Number one Cell phones
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- Manual for 6 Busssiness Class Flights
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
- The 10 Most Persuasive Forerunners in Innovation
- Desired Travel Objections Worldwide: Where to Go Straightaway
